Novel cross-talk within the IKK family controls innate immunity
Open accessAbstract
Members of the IKK {IκB [inhibitor of NF-κB (nuclear factor κB)] kinase} family play a central role in innate immunity by inducing NF-κB- and IRF [IFN (interferon) regulatory factor]-dependent gene transcription programmes required for the production of pro-inflammatory cytokines and IFNs. However, the molecular mechanisms that activate these protein kinases and their complement of physiological substrates remain poorly defined. Using MRT67307, a novel inhibitor of IKKϵ/TBK1 (TANK {TRAF [TNF (tumour-necrosis-factor)-receptor-associated factor]-associated NF-κB activator}-binding kinase 1) and BI605906, a novel inhibitor of IKKβ, we demonstrate that two different signalling pathways participate in the activation of the IKK-related protein kinases by ligands that activate the IL-1 (interleukin-1), TLR (Toll-like receptor) 3 and TLR4 receptors. One signalling pathway is mediated by the canonical IKKs, which directly phosphorylate and activate IKKϵ and TBK1, whereas the second pathway appears to culminate in the autocatalytic activation of the IKK-related kinases. In contrast, the TNFα-induced activation of the IKK-related kinases is mediated solely by the canonical IKKs. In turn, the IKK-related kinases phosphorylate the catalytic subunits of the canonical IKKs and their regulatory subunit NEMO (NF-κB essential modulator), which is associated with reduced IKKα/β activity and NF-κB-dependent gene transcription. We also show that the canonical IKKs and the IKK-related kinases not only have unique physiological substrates, such as IκBα, p105, RelA (IKKα and IKKβ) and IRF3 (IKKϵ and TBK1), but also have several substrates in common, including the catalytic and regulatory (NEMO and TANK) subunits of the IKKs themselves. Taken together, our studies reveal that the canonical IKKs and the IKK-related kinases regulate each other by an intricate network involving phosphorylation of their catalytic and regulatory (NEMO and TANK) subunits to balance their activities during innate immunity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Comparable findings in B16 cells were observed using two additional TBK1 inhibitors, MRT67307 and GSK8612, and the TBK1 PROTAC 3i.
“Comparable findings in B16 cells were observed using two additional TBK1 inhibitors, MRT67307 32 and GSK8612 33 (Extended Data Fig. 6g-h) and the TBK1-targeted proteolysis targeting chimera (TBK1 PROTAC 3i) 34 (Extended Data Fig. 6i).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [32]
BI605906 is a potent pharmacological inhibitor that shows high selectivity for IKKβ (IC50 = 380 nM) when tested against over 100 kinases in a panel screen.
“The first utilised BI605906, a potent pharmacological inhibitor that shows high selectivity for IKKβ (IC50 = 380 nM) when tested against over 100 kinases in a panel screen [36]”
From Proinflammatory NFkB signalling promotes mitochondrial dysfunction in skeletal muscle in response to cellular fuel overloading (2019) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 44 · Cited by 326
- Authors
- Clark, K., Peggie, M., Plater, L., Sorcek, R. J., Young, E. R. R., Madwed, J. B., Hough, J., McIver, E. G., & Cohen, P.
- Affiliations
- University of Dundee (GB)
- Boehringer Ingelheim (United States) (US)
- LifeArc (GB)
- Corresponding author
- Clark, Kristopher
- Peggie, Mark
- Plater, Lorna
- Cohen, Philip
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2011-01-27
- Volume
- 434
- Issue
- 1
- Pages
- 93-104
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2063548806
- Cited by
- 326
- References
- 44
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 26 · 2023: 20 · 2022: 33 · 2021: 19 · 2020: 23 · 2019: 18 · 2018: 22 · 2017: 21 · 2016: 19 · 2015: 16 · 2014: 20 · 2013: 23 · 2012: 20
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Biochemical Journal (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Funders
- University of Dundee
- Medical Research Council (MC_EX_G0800765, MC_G1000806)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- IKKε, TBK1, IKKβ, NEMO, tanks, NF-κB signaling, innate immunity, IRF3, TLR3, TLR4, IL-1 signaling, TNF signaling, protein phosphorylation, IκBα, p105, RelA, inflammatory cytokines, interferon regulation
- MeSH terms
- Cell Line, Cyclobutanes, Gene Expression Regulation, Humans, Immunity, Innate, Interleukin-1, Morpholines, Piperidines, Sulfonamides, Tumor Necrosis Factor-alpha, Molecular Structure, Signal Transduction, I-kappa B Proteins, Toll-Like Receptor 3, Toll-Like Receptor 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review